IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director M Anne Szostak Sells 3,000 Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

IDEXX Laboratories Trading Up 1.1 %

Shares of IDEXX Laboratories stock opened at $464.91 on Tuesday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The business has a 50 day moving average price of $428.35 and a 200 day moving average price of $453.32. The company has a market capitalization of $38.07 billion, a P/E ratio of 43.57, a P/E/G ratio of 3.47 and a beta of 1.37.

Hedge Funds Weigh In On IDEXX Laboratories

A number of institutional investors have recently made changes to their positions in the stock. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC grew its stake in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares during the period. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories in the 4th quarter valued at $30,000. Finally, Ashton Thomas Securities LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $37,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on IDXX shares. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Bank of America raised their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.